白云山(00874.HK)：注射用青霉素钠0.96g(160万单位)通过仿制药质量和疗效一致性评价

Core Viewpoint - The announcement highlights that Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.'s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval for its injectable penicillin sodium product, which is expected to enhance its market competitiveness [1] Group 1 - The product, injectable penicillin sodium 0.96g (1.6 million units), has passed the consistency evaluation for generic drug quality and efficacy [1] - The research and development expenses incurred by Tianxin Pharmaceutical for this product amount to approximately RMB 2.5926 million (unaudited) [1] - The approval is seen as a positive development for the company's product portfolio, potentially increasing its market share [1]